Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Managing Nonmetastatic Castration-resistant Prostate Cancer

Open access
Mateo, Joaquin, Fizazi, Karim, Gillessen, Silke, Heidenreich, Axel, Perez-Lopez, Raquel, Oyen, Wim J.G., Shore, Neal, Smith, Matthew, Sweeney, Christopher, Tombal, Bertrand, Tomlins, Scott A., de Bono, Johann S. · 2019 · European Urology

Abstract

CONTEXT: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a rapidly evolving field that merits detailed investigation. OBJECTIVE: To review current nmCRPC management practices and identify opportunities for improving care of nmCRPC patients. EVIDENCE ACQUISITION: A literature search up to July 2018 was conducted, including clinical trials and clinical practice guidelines (National Comprehensive Cancer Network, European Society for Medical Oncology, European Association of Urology, Prostate Cancer Clinical Trials Working Group, Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence). Keywords included prostate cancer, nonmetastatic, castration resistance, rising PSA, and biochemical relapse. EVIDENCE SYNTHESIS: Recommendations regarding indications for, and frequency of, imaging and PSA testing, as well as for initiating systemic therapy in nmCRPC are based on PSA rise kinetics and symptoms. Both enzalutamide and apalutamide have been shown to significantly increase metastasis-free survival in phase III placebo-controlled randomised trials in nmCRPC patients with PSA doubling time (DT) ≤10 mo. The expected impact of new imaging techniques in the assessment of nmCRPC is also reviewed. CONCLUSIONS: nmCRPC is a heterogeneous disease; while observation may be an option for some patients, enzalutamide and apalutamide may be appropriate to treat nmCRPC patients with PSA-DT ≤10 mo. The emergence of more accurate imaging modalities as well as circulating tumour biomarker assays will likely redefine the assessment of nmCRPC in the near future. PATIENT SUMMARY: Herein, we review key literature and clinical practice guidelines to summarise the optimal management of patients with prostate cancer and rising prostate-specific antigen despite castrate testosterone levels, but with no evidence of distant metastasis on traditional imaging. New drugs are being developed for this disease setting; novel imaging and tumour biomarker blood tests are likely to define this disease state more accurately.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2018.07.035

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 158

Metadata

Authors
Mateo, J., Fizazi, K., Gillessen, S., Heidenreich, A., Perez-Lopez, R., Oyen, W. J. G., Shore, N., Smith, M., Sweeney, C., Tombal, B., Tomlins, S. A., & de Bono, J. S.
Venue
European Urology
Publisher
Elsevier BV
Published
2019-02
Volume
75
Issue
2
Pages
285-293
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2885695264
Cited by
158
References
4
FWCI
14.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing Nonmetastatic Castration-resistant Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2018.07.035
The paper
Mateo, J., Fizazi, K., Gillessen, S., Heidenreich, A., Perez-Lopez, R., Oyen, W. J. G., Shore, N., Smith, M., Sweeney, C., Tombal, B., Tomlins, S. A., & de Bono, J. S. (2019). Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2018.07.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.